The MAHA era is here. RFK Jr.’s troubles are only beginning

To execute his promises on health, RFK Jr. faces tough challenges on vaccines, chronic disease, and big business.

February 5, 2025 Check out STAT+

Sponsored By

Catch STAT's Brittany Trang and Casey Ross in conversation at a Monday LinkedIn Live event about the rapidly changing nature of AI in health and medicine. Sign up here.

Anna Moneymaker/Getty Images STAT+ | The MAHA era is here. RFK Jr.'s troubles are only beginning Can RFK Jr. and MAHA transform U.S. health policy? Tough issues include vaccine promises, chronic disease, and entrenched opposition from big business. By Isabella Cueto USDA milk testing shows different strain of H5N1 bird flu in Nevada dairy herds The strain, which has circulated in wild birds and led to the death of a Louisiana patient last month, makes prospects for containment in cows appear dim. By Helen Branswell STAT+ | Trump's pick for science adviser is a rarity among his nominees — he's not controversial In a field of controversial Trump nominees, the proposed director of the Office of Science and Technology Policy has broad support By Jonathan Wosen José A. Alvarado Jr. for STAT STAT+ | What happens when a rare disease drug seems to work, but the health care system doesn't? An Amgen therapy has been used to treat a rare form of epilepsy, but that's no guarantee it will make it to market, or that generics will be accessible. By Ed Silverman Q&A: How institutions have responded to the gender-affirming care executive order, one week later A lot of people are "working tirelessly to prevent interruptions in care" and research will get harder but will continue, said one adolescent health expert. By Theresa Gaffney STAT+ | Personalized cancer vaccine shows potential in kidney cancer In the Phase 1 study, nine people with advanced kidney cancer became cancer-free after receiving personalized vaccines. By Elizabeth Cooney Adobe Opinion: We are all complicit in the big lie of health insurance Insurers have powerful market incentives to keep rationing hidden, to avoid losing business to competitors more willing and able to mislead. By M. Gregg Bloche STAT+ | Teladoc to buy home testing company Catapult for $65 million The virtual care giant hopes that Catapult's "wellness exam," including a blood sample test, will help it draw more people into its chronic disease programs. By Mario Aguilar

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser